在采用检测阴性设计的COVID-19疫苗有效性评估中考虑COVID-19与流感疫苗接种相关性的影响
该研究利用多州VISION疫苗有效性网络数据,评估在检测阴性设计的COVID-19疫苗有效性(VE)研究中,考虑流感疫苗接种状态或纳入/排除流感阳性对照对二价疫苗VE估计的影响。分析涵盖2022年10月至2023年2月SARS-CoV-2与流感共同流行期间的就诊事件,结果显示COVID-19 VE估计稳健,大多数VE估计变化小于5个百分点。
要点
- 考虑流感疫苗接种状态或纳入/排除流感阳性对照后,COVID-19 VE估计稳健,大多数变化小于5个百分点。
- 对照中流感阳性患者比例较高、流感疫苗接种覆盖率或VE可能影响这些发现。
- 潜在偏倚应继续评估。
核心结论
- 考虑流感疫苗接种状态或纳入/排除流感阳性对照时,COVID-19 VE估计稳健,大多数VE估计变化小于5个百分点。
研究设计与样本
- 利用多州VISION疫苗有效性网络数据,采用检测阴性设计,分析2022年10月至2023年2月SARS-CoV-2与流感共同流行期间的急诊/紧急护理就诊和住院事件。
主要发现
- 当考虑流感疫苗接种状态或纳入/排除流感阳性对照时,针对COVID-19相关住院和急诊/紧急护理就诊的大多数VE估计变化小于5个百分点。
局限性
- 对照中流感阳性患者比例较高、流感疫苗接种覆盖率或VE可能影响这些发现;潜在偏倚应继续评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Test-negative-design COVID-19 vaccine effectiveness (VE) studies use symptomatic SARS-CoV-2-positive individuals as cases and symptomatic SARS-CoV-2-negative individuals as controls to evaluate COVID-19 VE. To evaluate the potential bias introduced by the correlation of COVID-19 and influenza vaccination behaviors, we assessed changes in estimates of VE of bivalent vaccines against COVID-19-associated hospitalizations and emergency department/urgent care (ED/UC) encounters when considering influenza vaccination status or including or excluding influenza-positive controls using data from the multi-state VISION vaccine effectiveness network. Analyses included encounters during October 2022 - February 2023, a period of SARS-CoV-2 and influenza cocirculation. When considering influenza vaccination status or including or excluding influenza-positive controls, COVID-19 VE estimates were robust, with most VE estimates against COVID-19-associated hospitalization and ED/UC encounters changing less than 5 percentage points. Higher proportions of influenza-positive patients among controls, influenza vaccination coverage, or VE could impact these findings; the potential bias should continue to be assessed.
引用
- Payne AB, Ciesla AA, Rowley EAK, et al. Impact of accounting for correlation between COVID-19 and influenza vaccination in a COVID-19 vaccine effectiveness evaluation using a test-negative design. Vaccine. 2023. PMID: 38000964. doi:10.1016/j.vaccine.2023.11.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。